Celgene files patent infringement charges against Actavis and Abrika over generic versions of ADHD drug Focalin XR®
Clients Celgene Corporation
Jones Day represented Celgene Corporation in a Hatch-Waxman patent infringement action involving Celgene's branded ADHD drug Focalin XR®. This matter concluded through a mutually agreeable settlement.
Celgene Corporation, et al. v. Actavis South Atlantic, LLC and Abrika Pharmaceuticals, Inc., Case No. 3-07-cv-05367 (D.N.J.) (Judge Wolfson)